TO TON TO TON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sorensen et al.

Serial No.: 09/577,694

Group Art Unit: 1772

Filed: May 22, 2000

Examiner: Hon, Sow Fun

For: Injection - Molded Stopper For Medical Containers

EXPRESS MAIL CERTIFICATE

Express Mail Label Certificate No.: EV 246876885 US

Date of Deposit: October 6, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Request for Continued Examination (RCE) Transmittal (in duplicate)
- 2. Amendment under 37 C.F.R.1.111 (7 pages)
- 3. Petition and Fee For Extension of Time (in duplicate)

is being deposited with the United States Postal Service as express mail label no. EV 246876885 US in an envelope addressed to:

MS: RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on October 6, 2003

Rashida Haji
(name of person mailing paper)

(signature of person mailing paper)

PTO/SB/30 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are require

Request For Continued Examination (RCE) Transmittal

Address to: Commissioner for Patents **Box RCE** Washington, DC 20231

d to respond to a collection of information unless it contains a valid OMB control number.		
Application Number	09/577,694	
Filing Date	05/22/2000	>
First Named Inventor	Anne Sorensen	360
Art Unit	1772	8, 5
Examiner Name	Hon, Sow Fun	10
Attorney Docket Number	5762.200-US	123

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1.	Submission required under 37 CFR 1.114	
	a. Previously submitted	
	i. Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on	_
	li. Consider the arguments in the Appeal Brief or Rely Brief previously filed on	_
	lii. Other	
-	b. Fnclosed	
	I. Amendment/Reply iii. Information Disclosure Statement	(IDS)
	ii. Affidavit(s)/ Declaration(s) iv. Other	
2. (Miscellaneous	
	Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a	
	a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required b. Other)
، (
3. (The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to	
	a. Deposit Account No. 14-1447	
	i. RCE fee required under 37 CFR 1.17(e)	
	ii. Extension of time fee (37 CFR 1.136 and 1.17)	
	iii. Other	
	b. Check in the amount of \$enclosed	
	c. Payment by credit card (Form PTO-2038 endosed)	1000
	WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
	SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
Name Signal	(Print/Type) Marc A. Began Registration No. (Attorney/Agent)	48,829
Signal	Bate October 6, 2003	;
Lhorob	CERTIFICATE OF MAILING OR TRANSMISSION	
shown		n an envelope fice on the date
Name (Print/Type)	
Signatt	Date	
gatheri	Page I of 2 Ilection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to ess) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minuteing, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information of the USPTO. The properties of Complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information of the USPTO. The properties of Complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information of the USPTO. The properties of the USPTO	Any comments on the

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Box RCE, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

770.00 DA



Attorney Docket No.: 5762.200-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sorensen et al.

Serial No.: 09/577,694

Group Art Unit: 1772

Filed: May 22, 2000

Examiner: Hon, Sow Fun

For: Injection - Molded Stopper For Medical Containers



AMENDMENT UNDER 37 C.F.R. 1.111

Assistant Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed, April 8, 2003, Applicants respectfully request entry of the following amendment and reconsideration of the pending claims.

In the Claims

Please cancel claims 1-42 and add new claims 43 to 60.

Claims (1-42) - Cancelled

43. (New) A stopper comprising an injection-mouldable material made of a combination of butyt based rubber and a thermoplastic polymer, characterized in that the butyl based rubber is present in an amount of 70-90 % by weight and the thermoplastic polymer is present in an amount of 30-10 % by weight wherein the thermoplastic polymer is selected from the group of polyolefines consisting of polypropylene and polyethylene and wherein the combination of the butyl based rubber and the